At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GENB Generate Biomedicines
Pre-Mkt 11-10 06:22:49 EST
14.18
+1.12
+8.58%
盘前14.49
+0.31+2.19%
05:44 EST
High14.43Low12.93Vol669.53K
Open13.25D1 Closing13.06Amplitude11.49%
Mkt Cap1.82BTradable Cap854.89MTotal Shares128.19M
T/O9.40MT/O Rate1.11%Tradable Shares60.29M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Kapoor Reiterates Buy on Generate Biomedicines, Keeping $30 Price Target Amid Encouraging CAR-T and Anthropic AI Progress
TIPRANKS  ·  10-29
Kapoor Reiterates Buy on Generate Biomedicines, Keeping $30 Price Target Amid Encouraging CAR-T and Anthropic AI Progress
Generate Biomedicines Presents Phase 3 Asthma Program for Twice-Yearly GB-0895
Reuters  ·  10-24
Generate Biomedicines Presents Phase 3 Asthma Program for Twice-Yearly GB-0895
Generate Biomedicines Presents at Guggenheim, Jefferies Healthcare Conferences
Reuters  ·  10-22
Generate Biomedicines Presents at Guggenheim, Jefferies Healthcare Conferences
Pleasing Signs As A Number Of Insiders Buy Generate Biomedicines Stock
Simply Wall St.  ·  10-19
Pleasing Signs As A Number Of Insiders Buy Generate Biomedicines Stock
Generate Biomedicines management to meet with Cantor
TIPRANKS  ·  10-17
Generate Biomedicines management to meet with Cantor
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
TIPRANKS  ·  10-14
Generate Biomedicines, Zealand Pharma enter protein therapeutics pact
Zealand Pharma Partners with Generate Biomedicines on AI-Designed Protein Therapeutics for Metabolic Diseases
Reuters  ·  10-14
Zealand Pharma Partners with Generate Biomedicines on AI-Designed Protein Therapeutics for Metabolic Diseases
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
THOMSON REUTERS  ·  10-14
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines - to Receive $30 Mln Upfront, up to $1.20 Bln in Milestones, Plus Royalties
THOMSON REUTERS  ·  10-14
Generate Biomedicines - to Receive $30 Mln Upfront, up to $1.20 Bln in Milestones, Plus Royalties
Generate Biomedicines - Co to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
THOMSON REUTERS  ·  10-14
Generate Biomedicines - Co to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
Generate Biomedicines - to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
THOMSON REUTERS  ·  10-14
Generate Biomedicines - to Lead Research; Zealand Pharma to Handle Clinical Development and Commercialization
Zealand Pharma, Generate Strike Obesity Drug Deal Worth up to $1.2 Billion, Bloomberg News Reports
Reuters  ·  10-14
Zealand Pharma, Generate Strike Obesity Drug Deal Worth up to $1.2 Billion, Bloomberg News Reports
Zealand Pharma Makes Deal with Generate Worth up to $1.2 Billion - Bloomberg News
THOMSON REUTERS  ·  10-14
Zealand Pharma Makes Deal with Generate Worth up to $1.2 Billion - Bloomberg News
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-05
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.
Seven new option listings on October 2nd
TIPRANKS  ·  10-02
Seven new option listings on October 2nd
Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)
TIPRANKS  ·  10-02
Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)
Generate Biomedicines - Gb-5267 Targets Muc16 Biomarker in over 80% of Ovarian Tumors
THOMSON REUTERS  ·  10-01
Generate Biomedicines - Gb-5267 Targets Muc16 Biomarker in over 80% of Ovarian Tumors
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ Car T Therapy for Ovarian Cancer
THOMSON REUTERS  ·  10-01
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ Car T Therapy for Ovarian Cancer
Generate Biomedicines - Gb-5267 Treatment Designed to Avoid Pre-Infusion Chemotherapy
THOMSON REUTERS  ·  10-01
Generate Biomedicines - Gb-5267 Treatment Designed to Avoid Pre-Infusion Chemotherapy
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.
Dow Jones  ·  09-09
Generate Biomedicines Price Target Maintained with a $30.00/Share by HC Wainwright & Co.

Introduction

Company Name.
Generate Biomedicines
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Generate Biomedicines, Inc. was incorporated in August 2018 under Delaware law. As a clinical-stage generative biology company, it pioneered an AI-driven biotechnology platform called the Generate Platform, which combines computational models with scalable biological hardware to design and develop novel therapeutic proteins. Its most advanced candidate, GB-0895, is a computationally engineered anti-TSLP monoclonal antibody currently in a pivotal Phase 3 trial for severe asthma. The platform's capabilities have been further demonstrated by advancing two additional oncology candidates into Phase 1 trials by 2026.
Issue price:
--